The following undated information from the Health Canada website describes some of the contents of licensed influenza vaccines in Canada.

Three influenza vaccines are licensed for use in Canada, two produced by Aventis Pasteur (Fluzone® and Vaxigrip®) and one by *ID Biomedical (Fluviral S/F®). All three are sterile suspensions prepared from influenza viruses propagated in chicken embryos. The virus is inactivated, purified and treated with an organic solvent to remove surface glycoproteins, producing a “split-virus” preparation that is intended to reduce vaccine reactogenicity. One dose (0.5 mL) of vaccine contains 15 µg of hemaglutinin of each of three antigens. The antigens are selected from two strains of influenza A and one strain of influenza B. The virus strains chosen for inclusion in influenza vaccine are reviewed annually to ensure that they include antigens that are expected to provide the best protection during the following winter. All three licensed vaccines use thimerosal (0.01%) as a preservative. Gelatin (0.05%) is used as a stabilizer in Fluzone®. Vaxigrip® may contain undetectable traces of neomycin, used during production.

Ingredients list from Influenza Vaccine Product Monographs

VAXIGRIP (r)

Influenza Virus Vaccine Trivalent Types A and B (Split Virion) 2002-2003 Formula - For 6 Months and Older For Active Immunization Against Influenza

DESCRIPTION

VAXIGRIP (r) [Inactivated Influenza Vaccine Trivalent Types A and B (Split Virion)], for intramuscular use, is a sterile suspension prepared from influenza viruses propagated in chicken embryos. The virus-containing fluids are harvested and the virus inactivated with formaldehyde and purified by zonal centrifugation. The virus is then chemically disrupted using Polyethylene Glycol p-isooctylphenyl Ether (Triton (r) X-100) producing a “split-antigen”. The split antigen is suspended in sodium phosphate-buffered, isotonic sodium chloride solution. The type and amount of viral antigens contained in VAXIGRIP (r) conform to the current requirements of the World Health Organization (WHO).1

For the 2002-2003 season, each dose (0.5 mL) contains the following:

- A/Panama/2007/99 (H3N2) (A/Moscow/10/99-like strain) 15 µg HA
- A/New Caledonia/20/99 (H1N1) 15 µg HA
- B/Shangdong/7/97 (B/Hong Kong/330/2001-like strain) 15 µg HA Thimerosal 2 µg Sodium Phosphate-Buffered, Isotonic Sodium Chloride Solution up to 0.5 mL
- Formaldehyde £30 µg
- VAXIGRIP (r) also contains Triton (r) X-100 and trace amounts of sucrose and neomycin.

http://www.vran.org/vaccines/flu/flu-ingredients.htm